Cost Effectiveness of Tofacitinib for the Treatment of Active Ankylosing Spondylitis in Greece.

Gourzoulidis GeorgeArgyro SolakidiMarina PsarraEleni NikitopoulouCharalampos Tzanetakos

Published in: Clinical drug investigation (2023)

Tofacitinib was estimated to be a cost-effective option for the treatment of active ankylosing spondylitis in Greece for both biologic-naive and biologic-experienced patients.

Keyphrases

ankylosing spondylitis
rheumatoid arthritis
disease activity
end stage renal disease
chronic kidney disease
ejection fraction
newly diagnosed
systemic lupus erythematosus
prognostic factors
combination therapy
hiv infected
smoking cessation
antiretroviral therapy